Navigation Links
Romark Laboratories Awarded Contract For Late-Stage Development Of New Influenza Drug
Date:2/28/2013

TAMPA, Fla., Feb. 28, 2013 /PRNewswire/ -- Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the advanced development of NT-300 (nitazoxanide) as a treatment of acute uncomplicated influenza. The value of the cost plus fixed-fee contract is up to $44 million.

(Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO

The contract will be administered through the Biomedical Advanced Research and Development Authority (BARDA).  BARDA, an agency within the Office of the Assistant Secretary for Preparedness and Response, supports advanced development of and procures medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. 

"There is a pressing need for new drugs to treat influenza," said Jean-Francois Rossignol , M.D., Ph.D., Chairman and Chief Science Officer of Romark.  "BARDA plays an important role in the advanced development of new countermeasures for public health threats such as pandemic influenza, and we are pleased to have the opportunity to work with them."

The contract award followed BARDA's solicitation of proposals for development of antiviral therapeutics with new mechanisms of action against influenza. Areas of interest to BARDA addressed by Romark's development plan include a novel mechanism of action, targeting of host factors, potential for broad spectrum antiviral activity and combination therapeutic approaches using an influenza antiviral and a host modulating therapeutic. Importantly, NT-300 is administered orally, and it is being proposed for treatment of seasonal as well as pandemic influenza.

Currently, there are only two classes of drugs approved in the United States for treating influenza, and only the neuraminidase inhibitors, oral Tamiflu® (oseltamivir) and inhaled Relenza® (zanamivir), are recommended for use. There has not been a new drug approved in the United States for treating influenza since Tamiflu® and Relenza® were approved in 1999. New drugs with different mechanisms of action could be important in overcoming drug resistance and providing better treatment for patients with influenza.

Romark will begin work under the contract immediately in an effort to complete the development and seek approval of NT-300 as a treatment of acute uncomplicated influenza. Activities covered by the contract include non-clinical and clinical development and regulatory activities required to submit and manage a New Drug Application. 

Romark's Phase 3 clinical trial will evaluate the efficacy and safety of NT-300 or NT-300 plus oseltamivir compared to a placebo or to oseltamivir alone in treating outpatients 13 to 65 years of age with acute uncomplicated influenza.

About NT-300
NT-300, a controlled release tablet for oral administration containing 300 mg of nitazoxanide (NTZ) as active ingredient, is being developed by Romark Laboratories for treatment of influenza. NTZ inhibits replication of a broad range of influenza viruses in cell culture assays, including oseltamivir- and amantadine-resistant strains, as well as other respiratory viruses that may cause flu-like symptoms in humans including the paramyxoviridae and the coronaviridae. In cell culture assays, NTZ and oseltamivir act synergistically in inhibiting replication of influenza viruses.  In a Phase 2b/3 clinical trial conducted in the United States during the 2010-2011 influenza season, NT-300 administered 600 mg orally twice daily for 5 days reduced the duration of symptoms of acute uncomplicated influenza compared to a placebo and reduced viral titers in nasal swabs collected during treatment.

About Romark Laboratories
Romark Laboratories, L.C. is a biopharmaceutical company committed to the discovery and development of innovative small molecule drugs for treating infectious diseases and cancers. The company is developing a new class of broad-spectrum antiviral drugs called thiazolides. Romark markets Alinia® (nitazoxanide) tablets, 500 mg and Alinia® (nitazoxanide) for Oral Suspension, 100 mg/5 mL in the United States.


'/>"/>
SOURCE Romark Laboratories, L.C.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immunotech Laboratories Receives $2M Funding Approval To Begin European Clinical Trials Testing For Companys Patented "IPF" HIV-AIDS Medicines
2. Breaking News: Video Interview With Harry Zhabilov of Immunotech Laboratories Inc.
3. Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Companys Growth and International Expansion Plan
4. Dr. Oz, Host Of The Dr. Oz Show, and Harry Zhabilov Of Immunotech Laboratories Discuss Immunotherapy Treatments For Cancer, HIV/AIDS
5. Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
6. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
7. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
8. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
9. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
10. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
11. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Research and Markets has ... Myeloma Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Multiple ... Myeloma market valuations and forecast, Multiple Myeloma ...
(Date:5/4/2016)... 2016 Research and ... Acute Myeloid Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors (UBA), the ... the latest addition to its family of Partner Firms. Headquartered in Mount Pleasant, ... human resources, and health care consumerism specialists. , “Partnering with UBA will enable ...
(Date:5/5/2016)... ... May 05, 2016 , ... An essential tool for researching ... certain Canadian provinces is now available from the International Association of Industrial Accident ... The report, Workers’ Compensation Laws as of January 1, 2016, is ...
(Date:5/5/2016)... ... May 05, 2016 , ... A recent survey by ... face challenges in getting employees to understand and use the free preventive care benefits ... nation’s leading non-profit business groups of large, self-insured public and private employers, MBGH found ...
(Date:5/5/2016)... Houston, TX (PRWEB) , ... May 05, 2016 , ... ... 2015 AIA/AAH Healthcare Design Awards, presented by the American Institute of Architects and the ... and designed by the renowned Perkins+Will and Harrell Architects, opened to patients in October ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TIME for Kids ... – today announced a new partnership to reach nearly 1 million children with important ... an instant and is the leading cause of accidental death in children one to ...
Breaking Medicine News(10 mins):